LY3041658

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyHidradenitis SuppurativaPsoriasisSkin Diseases

Phase 1

A Study of LY3041658 in Participants With Skin Diseases

CompletedNCT02896868

Eli Lilly and CompanyPsoriasis, Skin Diseases

Start: 2016-11-08End: 2019-03-19Target: 60Updated: 2019-05-03

A Study of LY3041658 in Healthy Participants

CompletedNCT04653168

Eli Lilly and CompanyHealthy

Start: 2020-12-07End: 2021-05-28Updated: 2021-06-18

A Study of Eltrekibart (LY3041658) in Healthy Participants

Active, not recruitingNCT07545590

Eli Lilly and CompanyHealthy

Start: 2026-04-21End: 2026-09-01Target: 60Updated: 2026-09-18

Phase 2

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

CompletedNCT04493502

Eli Lilly and CompanyHidradenitis Suppurativa

Start: 2020-08-26End: 2022-10-13Updated: 2023-04-28

Related Papers

A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.

2025-10-06